AZD5305

Phase 2Small molecule

AstraZeneca

AZD5305 is one of 109 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Prostate CancerRecruiting

Gastric CancerActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Metastatic Prostate CancerPhase 1/Phase 2

Active, not recruiting

Prostate CancerPreclinical

Recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

AZD5305

AstraZeneca

Phase 2

5 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Radiotherapy

NCT04550104

Q1 2029

PreclinicalRecruiting

Prostate Cancer

NCT07336446

Q2 2031

Phase 1/2Active, not recruiting

Metastatic Prostate Cancer

NCT05367440

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05573724·16 enrolled

Radiotherapy1 trial

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Recruiting·UUniversity of Leeds·Phase 1·NCT04550104·200 enrolled

Metastatic Prostate Cancer1 trial

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT05367440·174 enrolled

Prostate Cancer1 trial

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07336446·300 enrolled

Gastric Cancer1 trial

DESTINY-Gastric02: T-DXd in Gastric Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT04644068·187 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AZD5305. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD5305 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD5305. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD5305

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Q2 2031

Trials by Indication[1]

Advanced Solid Malignancies1 trial

Radiotherapy1 trial

Metastatic Prostate Cancer1 trial

Prostate Cancer1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News